Latest news at the ROI Laboratory
Award for one of our students
On September 18th, one of our students, Effrosyni Tsouri, was awarded the MSc. Molecular Mechanisms of Disease “Best Poster Award”, following the presentation of her first scientific poster. On the poster, she discussed the results of her internship at the department of Radiotherapy and Oncoimmunology.
Travel award for Pieter Roelofs
Pieter Roelofs received a travel award at the Deaminet 2020 conference in Palm Springs.
Our Radboud Oncologie Fonds ROI project has been awarded
Recently, "Bergh in het Zadel" awarded the Radboud Oncologie Fonds ROI project: "The effect of radiotherapy on immune cell landscape" with over 300.000 euro, thereby financing the full project.
Welcome at our LaboratoryThe experimental and clinical research program by the Radiotherapy & OncoImmunology Laboratory is aimed at:
Molecular Immunology programDendritic cells (DC) are the professional antigen presenting cells (APC) of our immune system. They are able to initiate immune responses against pathogens or tumors, but also have the capacity to prevent (auto)-immune responses harmful to the host. My research is centered around the molecular and functional analysis of DC in mouse and man. Applying different molecular approaches at the genomic and proteomic level a set of novel DC-antigens have been identified, including chemokines (DC-CK1, CXCL16), a novel multiple membrane spanning receptor (DC-STAMP), a transcription regulator (DC-SCRIPT). Knowledge regarding DC-immuno-biology is essential for the development and design of DC-based vaccines in mouse models as well as in clinical studies in cancer patients. More recently, regulatory T cells that are crucially involved in balancing the immune system are studied at the molecular and functional level as well as in immunotherapy of cancer.
VAMPAn important objective is the development of predictive profiles based on Vascular Architecture and Microenvironmental Parameters (VAMP). The ultimate goal is to provide a mechanistic basis for the optimization of treatments that combine radiotherapy with novel biological modifiers and for the development of patient selection strategies.
More information about the research program is in the section Research.